ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2025-8-1-44-50ojrdrt-417Research ArticleЯДЕРНАЯ МЕДИЦИНАNUCLEAR MEDICINEПЭТ/КТ с 18F-мета-фторбензилгуанидином (18F-МФБГ) при нейробластоме. Первый опыт в России: сравнение с данными сцинтиграфии с 123I-метайодбензилгуанидином (123I-МИБГ)18F-metafluorobenzylguanidine (18F-MFBG) PET/CT in Neuroblastoma. The First experience In Russia: Comparison with 123I-metaiodobenzylguanidine (123I-MIBG) Scintigraphyhttps://orcid.org/0000-0002-8476-7879ОджароваА. А.KrylovA. S.

115478 Москва, Каширское шоссе, 24

Alexander S. Krylov

24 Kashirskoye Shosse, Moscow, 115478

krilovas@rambler.ruhttps://orcid.org/0000-0003-3576-6156КрыловА. С.OdzharovaA. A.

Крылов Александр Сергеевич

+79037211777

 115478 Москва, Каширское шоссе, 24

Akgul A. Odzharova

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0001-7226-5129ТулинП. Е.TulinP. E.

115478 Москва, Каширское шоссе, 24

Pavel E. Tulin

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0002-1016-539XРубанскаяМ. В.RubanskayaM. V.

115478 Москва, Каширское шоссе, 24

Marina V. Rubanskaya

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0003-2969-0191НевзоровД. И.NevzorovD. I.

115478 Москва, Каширское шоссе, 24

Denis I. Nevzorov

24 Kashirskoye Shosse, Moscow, 115478

https://orcid.org/0000-0003-2312-6020НестероваН. И.NesterovaN. I.

115478 Москва, Каширское шоссе, 24

Natalia I. Nesterova

24 Kashirskoye Shosse, Moscow, 115478

Национальный медицинский исследовательский центp онкологии им. Н.Н. Блохина Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of OncologyRussian Federation202503042025814450Copyright © Оджарова А.А., Крылов А.С., Тулин П.Е., Рубанская М.В., Невзоров Д.И., Нестерова Н.И., 20252025Оджарова А.А., Крылов А.С., Тулин П.Е., Рубанская М.В., Невзоров Д.И., Нестерова Н.И.Krylov A.S., Odzharova A.A., Tulin P.E., Rubanskaya M.V., Nevzorov D.I., Nesterova N.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/417

Нейробластома является самой частой экстракраниальной солидной опухолью детского возраста. В 7 из 10 случаев нейробластома на момент постановки диагноза уже проявляется диссеминированным процессом. Из современных методов ядерной медицины в оценке нейробластомы наиболее важную роль играет сцинтиграфия с метайодбензилгуанидином — аналогом норадреналина, меченным 123I (123I-МИБГ). В настоящее время появился новый РФЛП 18F-МФБГ (меченый 18F аналог бензилгуанидина), который может использоваться в радионуклидной диагностике нейробластом. Наши клинические наблюдения показали идентичную данным сцинтиграфии с 123I-МИБГ диагностическую эффективность со значительно более быстрым клиренсом крови, чем 123I-МИБГ, что позволяет проводить исследования уже через 1 ч после внутривенного введения. В одном случае при ПЭТ/КТ с 18F-МФБГ были выявлены дополнительные опухолевые очаги, что позволило корректировать терапию, что, безусловно, имеет большое значение в клинической практике.

Neuroblastoma is the most frequent extracranial solid tumor of childhood. In 7 out of 10 cases, neuroblastoma is already disseminated at the time of diagnosis. Of the current nuclear medicine techniques, scintigraphy with methaiodobenzylguanidine, which is a 123I-labeled noradrenaline analog or (123I-MIBG), plays the most important role in the evaluation of neuroblastoma. Currently, a new PET-tracer, 18F-MFBG (18F-labeled benziguanidine analog), has emerged that can be used in the radionuclide diagnosis of neuroblastomas. Our clinical observations showed identical diagnostic efficiency to scintigraphy data with 123I-MIBG with significantly faster blood clearance than 123I-MIBG, which allows us to perform studies as early as 1 h after intravenous administration. In one case PET/CT with 18F-MIBG revealed additional tumor foci, which allowed to correct therapy, which is certainly of great importance in clinical practice.

нейробластомаонкопедиатрияПЭТ/КТОФЭКТ/КТ18F-метафторбензилгуанидин123I-метайодбензилгуанидинneuroblastomapediatric oncologyPET/CTSPECT/CT18F-metafluorobenzylguanidine123I-metaiodobenzylguanidineReferencesSharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011;41(5):345-53. https://doi.org/10.1053/j.semnuclmed.2011.05.001.Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011;41(5):345-53. https://doi.org/10.1053/j.semnuclmed.2011.05.001.Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and of 123I-MIBG: Clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987;15(4):170-7. https://doi.org/10.1002/mpo.2950150406.Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and of 123I-MIBG: Clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987;15(4):170-7. https://doi.org/10.1002/mpo.2950150406.Colavolpe C, Guedj E, Cammilleri S, et al. Utility of FDGPET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;51(6):828-31. https://doi.org/10.1002/pbc.21594.Colavolpe C, Guedj E, Cammilleri S, et al. Utility of FDGPET/CT in the follow-up of neuroblastoma which became MIBG-negative. Pediatr Blood Cancer. 2008;51(6):828-31. https://doi.org/10.1002/pbc.21594.Sharp SE, Shulkin BL, Gelfand MJ, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50(8):1237-43. https://doi.org/10.2967/jnumed.108.060467.Sharp SE, Shulkin BL, Gelfand MJ, et al. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009;50(8):1237-43. https://doi.org/10.2967/jnumed.108.060467.Taggart DR, Han MM, Yuach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and 18F-Ňuorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27(32):5343-9. https://doi.org/10.1200/JCO.2008.20.5732.Taggart DR, Han MM, Yuach A, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and 18F-Ňuorodeoxyglucose positron emission tomography to evaluate response aŌer iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol. 2009;27(32):5343-9. https://doi.org/10.1200/JCO.2008.20.5732.Huang SY, Bolch WE, Lee C, et al. Patient-specific dosimetry using pretherapy 124 Im-iodobenzylguanidine (124 I] mIBG) dynamic PET/CT imaging before 131I mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015;17(2):284-94. https://doi.org/10.1007/s11307-014-0783-7.Huang SY, Bolch WE, Lee C, et al. Patient-specific dosimetry using pretherapy 124 Im-iodobenzylguanidine (124 I] mIBG) dynamic PET/CT imaging before 131I΁mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2015;17(2):284-94. https://doi.org/10.1007/s11307-014-0783-7.Cistaro A, Yuartuccio N, Caobelli F, et al. 124 I-MIBG: a new promising positron-emiƫng radiopharmaceutical for the evaluation of neuroblastoma. Nuclear Med Rev. 2015;18(2):102-6. https://doi.org/10.5603/NMR.2015.0024.Cistaro A, Yuartuccio N, Caobelli F, et al. 124 I-MIBG: a new promising positron-emiƫng radiopharmaceutical for the evaluation of neuroblastoma. Nuclear Med Rev. 2015;18(2):102-6. https://doi.org/10.5603/NMR.2015.0024.Wartski M, Jehanno N, Michon J, et al. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma. Clin Nucl Med. 2015;40(12):969-70. https://doi.org/10.1097/RLU.0000000000000957.Wartski M, Jehanno N, Michon J, et al. Weak uptake of 123I-MIBG and 18F-FDOPA contrasting with high 18F-FDG uptake in stage I neuroblastoma. Clin Nucl Med. 2015;40(12):969-70. https://doi.org/10.1097/RLU.0000000000000957.Matsubara K, Watabe H, Kumakura Y, et al. Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for 18F FDOPA PET by a model with detailed dopamine pathway. Synapse. 2011;65(8):751-62. https://doi.org/10.1002/syn.20899.Matsubara K, Watabe H, Kumakura Y, et al. Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for 18F FDOPA PET by a model with detailed dopamine pathway. Synapse. 2011;65(8):751-62. https://doi.org/10.1002/syn.20899.Piccardo A, Lopci E, Foppiani L, et al. (18)F-DOPA PET/ CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma. Pediatr Radiol. 2014;44(3):355-61. https://doi.org/10.1007/s00247-013-2807-x.Piccardo A, Lopci E, Foppiani L, et al. (18)F-DOPA PET/ CT for assessment of response to induction chemotherapy in a child with high-risk neuroblastoma. Pediatr Radiol. 2014;44(3):355-61. https://doi.org/10.1007/s00247-013-2807-x.Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447-55. https://doi.org/10.1002/cncr.23469.Kayani I, Bomanji JB, Groves A, et al. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer. 2008;112(11):2447-55. https://doi.org/10.1002/cncr.23469.Gains JE, Aldridge MD, Mattoli MV, et al. 68Ga-DOTATATE and 123I-MIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: Implications for molecular radiotherapy. Nucl Med Commun 2020;41(11):1169-77. https://doi.org/10.1097/MNM.0000000000001265.Gains JE, Aldridge MD, Mattoli MV, et al. 68Ga-DOTATATE and 123I-MIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: Implications for molecular radiotherapy. Nucl Med Commun 2020;41(11):1169-77. https://doi.org/10.1097/MNM.0000000000001265.Telli T, Ergƺn EL, Salanci BV, et al. The complementary role of 68Ga-DOTATATE PET/CT in neuroblastoma. Clin Nucl Med. 2020;45(4):326-29. https://doi.org/10.1097/RLU.0000000000002961.Telli T, Ergƺn EL, Salanci BV, et al. The complementary role of 68Ga-DOTATATE PET/CT in neuroblastoma. Clin Nucl Med. 2020;45(4):326-29. https://doi.org/10.1097/RLU.0000000000002961.Николаева Е.А, Крылов АС, Каспшик СМ и др. Сравнение сцинтиграфии с 123I-метайодбензилгуанидином и 99mTcтектротидом у пациентов с опухолями нейрогенной природы. Российский журнал детской гематологии и онкологии. 2024;11(1):36-43. https://doi.org/10.21682/2311-1267-2024-11-1-36-43.Nikolaeva EA, Krylov AS, Kasprshyk SM, et al. Comparison of scintigraphy with 123I-MIBG and 99mTc-tectrotyde in patients with tumors of a neurogenic nature. Russian Journal of Pediatric Hematology and Oncology. 2024;11(1):36-43. (In Russ.). https://doi.org/10.21682/2311-1267-2024-11-1-36-43.Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261(1):243-57. https://doi.org/10.1148/radiol.11101352.Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261(1):243-57. https://doi.org/10.1148/radiol.11101352.Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45(11):2009-24. https://doi.org/10.1007/s00259-018-4070-8.Bar-Sever Z, Biassoni L, Shulkin B, et al. Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018;45(11):2009-24. https://doi.org/10.1007/s00259-018-4070-8.Zhang H, Huang R, Pillarsetty NVK, et al. Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging. 2014;41(2):322-32. https://doi.org/10.1007/s00259-013-2558-9.Zhang H, Huang R, Pillarsetty NVK, et al. Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging. 2014;41(2):322-32. https://doi.org/10.1007/s00259-013-2558-9.Hu B, Vavere AL, Neumann KD, et al. A practical, automated synthesis of meta-(18)F Ňuorobenzylguanidine for clinical use. ACS Chem Neurosci. 2015;18(6):1870-9. https://doi.org/10.1021/acschemneuro.5b00202.Hu B, Vavere AL, Neumann KD, et al. A practical, automated synthesis of meta-18)FŇuorobenzylguanidine for clinical use. ACS Chem Neurosci. 2015;18(6):1870-9. https://doi.org/10.1021/acschemneuro.5b00202.Samim F, Blom T, Poot AJ, et al. 18F mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50(4):1146-57. https://doi.org/10.1007/s00259-022-06063-6.Samim F, Blom T, Poot AJ, et al. 18F mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2023;50(4):1146-57. https://doi.org/10.1007/s00259-022-06063-6.Pandit-Taskar N, Zanzonico P, Staton KD, et al. Biodistribution and dosimetry of 18F-MetaFluorobenzylguanidine: a first-inhuman PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59(1):147-53. https://doi.org/10.2967/jnumed.117.193169.Pandit-Taskar N, Zanzonico P, Staton KD, et al. Biodistribution and dosimetry of 18F-MetaFluorobenzylguanidine: a first-inhuman PET/CT imaging study of patients with neuroendocrine malignancies. J Nucl Med. 2018;59(1):147-53. https://doi.org/10.2967/jnumed.117.193169.

The authors declare that there are no conflicts of interest present.